Sternberg CN - Search Results

1

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.

Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, Tagawa ST, Molina AM, Sternberg CN, Nanus DM, Mosquera JM, Elemento O, Sonpavde GP, Grivas P, Vogelzang NJ, Faltas BM. Shohdy KS, et al. Among authors: sternberg cn. Br J Cancer. 2022 Feb;126(3):430-439. doi: 10.1038/s41416-021-01648-8. Epub 2022 Jan 19. Br J Cancer. 2022. PMID: 35046520 Free PMC article.

2

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.

Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, Bosl GJ. Seidman AD, et al. Among authors: sternberg cn. Cancer. 1991 Dec 15;68(12):2561-5. doi: 10.1002/1097-0142(19911215)68:12<2561::aid-cncr2820681205>3.0.co;2-g. Cancer. 1991. PMID: 1933802 Clinical Trial.

3

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy.

Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Geller NL, et al. Among authors: sternberg cn. Cancer. 1991 Mar 15;67(6):1525-31. doi: 10.1002/1097-0142(19910315)67:6<1525::aid-cncr2820670611>3.0.co;2-8. Cancer. 1991. PMID: 2001540

4

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al. Sternberg CN, et al. Cancer. 1989 Dec 15;64(12):2448-58. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. Cancer. 1989. PMID: 2819654

5

Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder.

Sternberg CN, Arena MG, Calabresi F, De Carli P, Platania A, Zeuli M, Giannarelli D, Cancrini A, Pansadoro V. Sternberg CN, et al. Cancer. 1993 Sep 15;72(6):1975-82. doi: 10.1002/1097-0142(19930915)72:6<1975::aid-cncr2820720631>3.0.co;2-i. Cancer. 1993. PMID: 8364877 Clinical Trial.

6

Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.

Sternberg CN, Vogelzang NJ. Sternberg CN, et al. Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S105-15. doi: 10.1016/s1040-8428(03)00068-4. Crit Rev Oncol Hematol. 2003. PMID: 12850531 Review.

7

Signal-transduction inhibitors in renal cell carcinoma.

Vogelzang NJ, Sternberg CN. Vogelzang NJ, et al. Among authors: sternberg cn. BJU Int. 2007 May;99(5 Pt B):1289-95. doi: 10.1111/j.1464-410X.2007.06833.x. BJU Int. 2007. PMID: 17441926 Review. No abstract available.

8

Novel agents for muscle-invasive and advanced urothelial cancer.

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Sonpavde G, et al. Among authors: sternberg cn. BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005203 Review.

9

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.

Sonpavde G, Hutson TE, Sternberg CN. Sonpavde G, et al. Among authors: sternberg cn. Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253. Expert Opin Investig Drugs. 2008. PMID: 18230058 Review.

10

Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.

Sonpavde G, Sternberg CN. Sonpavde G, et al. Among authors: sternberg cn. BJU Int. 2008 Nov;102(9 Pt B):1354-60. doi: 10.1111/j.1464-410X.2008.07982.x. BJU Int. 2008. PMID: 19035904 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

472 results

Search Page

Filters